Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line data anticipated in 2H 2026 4WARD trial protocol refined, increasing confidence in successful outcome
Wed, 02 Apr 2025 13:25:00 GMT United Kingdom research & development tax credits for the three months and year ended December 31, 2024 were a debit of $1.2 million and a credit of 0.8 million compared to credits $0.4 million and $3 ...
Tue, 25 Mar 2025 04:01:00 GMT Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line ...
Thu, 20 Mar 2025 15:31:00 GMT VICTORIA, BC, March 20, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia ... disease and other critical disease areas. This news release includes forward-looking statements and ...
Thu, 20 Mar 2025 07:32:00 GMT VICTORIA, BC, March 20, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology ...
Tue, 18 Mar 2025 05:01:00 GMT To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com. Any statements in this press release about ... Company's annual report filed with the ...
